<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03510676</url>
  </required_header>
  <id_info>
    <org_study_id>P41302</org_study_id>
    <nct_id>NCT03510676</nct_id>
  </id_info>
  <brief_title>The ILLUMINA Study. (ILLUMINA)</brief_title>
  <acronym>ILLUMINA</acronym>
  <official_title>Innovative siroLimus seLf Expanding drUg-eluting Stent for the treatMent of perIpheral Disease: Evaluation of Safety aNd efficAcy. The ILLUMINA Study. (ILLUMINA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CID - Carbostent &amp; Implantable Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CID - Carbostent &amp; Implantable Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the prospective, multicentre, single-arm study is to assess safety and efficacy of&#xD;
      a drug eluting stent in Nitinol alloy (NiTiDES) in term of vessel patency and composite&#xD;
      event-free survival rate up to two years follow-up in focal/medium length lesions in patients&#xD;
      with ischemic obstruction of superficial femoral arteries or/and proximal popliteal arteries.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 26, 2016</start_date>
  <completion_date type="Actual">March 7, 2019</completion_date>
  <primary_completion_date type="Actual">March 7, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival rate from Major Adverse Events</measure>
    <time_frame>12 months after procedure</time_frame>
    <description>Freedom from Clinical Events Committee (CEC) adjudicated Major Adverse Event (death, target limb amputation, target limb ischemia requiring surgical intervention or surgical repair of target vessel or clinically-driven target lesion revascularization) or worsening of the Rutherford score by 2 classes, or to class 5 or 6.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary patency (absence of clinically-driven target lesion revascularization or binary restenosis)</measure>
    <time_frame>12 months after procedure</time_frame>
    <description>Primary patency is defined as absence of clinically-driven target lesion revascularization or binary restenosis; binary restenosis is defined as a peak systolic velocity ratio (PSVR) &gt;2.4 (duplex evaluation)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>NiTiDES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NiTiDES</intervention_name>
    <arm_group_label>NiTiDES</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Clinical&#xD;
&#xD;
          -  Patient must be over 18 years inclusive at the time of consent prior to participation&#xD;
             in the study and must understand the purpose of this study and be willing to adhere to&#xD;
             the study procedures described in this protocol;&#xD;
&#xD;
          -  A female of childbearing potential may be enrolled, provided she has a negative&#xD;
             pregnancy test at screening;&#xD;
&#xD;
          -  Patient has signed and dated the informed consent;&#xD;
&#xD;
          -  Patient has symptoms of peripheral arterial disease classified as Rutherford Category&#xD;
             (2-4); patients with Rutherford Category 2 can be included only if a conservative&#xD;
             and/or medication therapy was unsuccessful.&#xD;
&#xD;
          -  Patient has a resting ABI &lt;0.9 or at exercise if resting ABI is normal; patient with&#xD;
             incompressible arteries (ABI &gt;1.2) at rest or at exercise must have a toe-brachial&#xD;
             index (TBI) &lt;0.8.&#xD;
&#xD;
        Angiographic&#xD;
&#xD;
          -  Patient has one documented stenotic or occluded atherosclerotic lesion (lesion length&#xD;
             ≤ 14 cm) of the above-the-knee femoropopliteal artery, in one limb, that meet all of&#xD;
             the inclusion criteria and none of the exclusion criteria;&#xD;
&#xD;
          -  Patient has a de novo or restenotic lesion with &gt;50% stenosis documented&#xD;
             angiographically and no prior stent in the target lesion;&#xD;
&#xD;
          -  The target lesion must be appropriately covered (margin of 5.0 mm on both sides of the&#xD;
             stent) by one or two study stents (NiTiDES). Any occurred dissection of the target&#xD;
             vessel must be treated with an additional stent (NiTiDES);&#xD;
&#xD;
          -  Tandem lesions are allowed if the distance between 2 lesions is ≤ 3 cm and the total&#xD;
             length of all lesions ≤ 14 cm;&#xD;
&#xD;
          -  Guidewire successfully passed the lesion through the lumen.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Clinical&#xD;
&#xD;
          -  Patient is pregnant or breast-feeding;&#xD;
&#xD;
          -  Patient is simultaneously participating in another investigational drug or device&#xD;
             study;&#xD;
&#xD;
          -  Patient has any planned surgical or interventional procedure within 30 days after the&#xD;
             study procedure;&#xD;
&#xD;
          -  Clinical conditions, disorders or allergies that limit the use of anti-platelet and/or&#xD;
             anticoagulant therapy;&#xD;
&#xD;
          -  Severe allergy to the contrast medium or drugs used during the procedure;&#xD;
&#xD;
          -  Patients with known hypersensitivity or allergies to Sirolimus, fatty acids (such as&#xD;
             stearic acid, palmitic acid, behenic acid) or the metal components of the stent (such&#xD;
             as Nickel, Titanium and Tantalum);&#xD;
&#xD;
          -  Serum creatinine &gt; 2.5 mg/dl;&#xD;
&#xD;
          -  Myocardial infarction within the 90 days prior to enrollment;&#xD;
&#xD;
          -  Hypercoagulable state;&#xD;
&#xD;
          -  Uncontrollable hypertension;&#xD;
&#xD;
          -  Life expectancy &lt; 12 months;&#xD;
&#xD;
          -  Aneurysmal disease of abdominal aorta, iliac artery and popliteal artery;&#xD;
&#xD;
          -  Gastrointestinal bleeding;&#xD;
&#xD;
          -  Stroke within the 180 days prior to enrollment;&#xD;
&#xD;
          -  Concomitant therapies such as: atherectomy, cryoplasty, scoring / cutting balloons.&#xD;
&#xD;
        Angiographic&#xD;
&#xD;
          -  Patient has significant stenosis or occlusion of inflow tract not successfully treated&#xD;
             before this procedure;&#xD;
&#xD;
          -  Patient has had previous stenting of target vessel;&#xD;
&#xD;
          -  Patient lacks at least one patent vessel of runoff with &lt;50% stenosis throughout its&#xD;
             course;&#xD;
&#xD;
          -  Patient has untreated angiographically-evident thrombus in the target lesion;&#xD;
&#xD;
          -  Patients intended to be treated with more than two stents in the target lesion unless&#xD;
             additional stent required in case of dissection;&#xD;
&#xD;
          -  Patient intended to receive different stent from NiTiDES in target lesion;&#xD;
&#xD;
          -  Technically unsuccessful Percutaneous Transluminal Angioplasty (PTA) procedure, for&#xD;
             example due to the impossibility of accessing the stenotic site with a delivery system&#xD;
&#xD;
          -  Lesions considered untreatable with PTA or other interventional techniques;&#xD;
&#xD;
          -  Inflow lesion ≥15 cm long or occlusion (any length) in the ipsilateral Iliac artery;&#xD;
&#xD;
          -  Not successfully treated &lt; 15 cm long inflow lesion in the ipsilateral iliac artery&#xD;
             [Treatment of inflow lesion must precede patient enrollment and target lesion&#xD;
             treatment. No Drug Eluting Stents (DES) and / or Drug Eluting Balloon (DEB) allowed&#xD;
             for the treatment of inflow lesions];&#xD;
&#xD;
          -  Lesions in contralateral Superficial Femoral Artery (SFA) that require intervention&#xD;
             during the index procedure, or within 30 days after the index procedure. Lesions in&#xD;
             contralateral SFA can be treated either &gt;30 days prior to or &gt; 30 days after the index&#xD;
             procedure;&#xD;
&#xD;
          -  Patient with stenosis adjacent to an aneurysmal lesion of diameter at least twice the&#xD;
             lumen of the native vessel;&#xD;
&#xD;
          -  Lesions localized in the two distal thirds of the popliteal artery (or at the knee&#xD;
             joint, generally considered).&#xD;
&#xD;
        Others.&#xD;
&#xD;
        • Patients under judicial protection, tutorship or curatorship (for France only).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dierk Scheinert</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Leipzig, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Polyclinique Les Fleurs</name>
      <address>
        <city>Ollioules</city>
        <zip>83190</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Privé Claude Galien</name>
      <address>
        <city>Quincy sous Sénart</city>
        <zip>91480</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Gertrauden Krankenhaus GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10713</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regiomed GefäBzentrum Sonneberg</name>
      <address>
        <city>Sonneberg</city>
        <zip>96515</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Cecilia Hospital</name>
      <address>
        <city>Cotignola</city>
        <state>Ravenna</state>
        <zip>48033</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Raffaele Hospital</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 4, 2018</study_first_submitted>
  <study_first_submitted_qc>April 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2018</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

